Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Prostate Cancer
Debate on PSA Prostate Cancer Screening Redux
By
Phoebe Starr
Genitourinary Cancers Symposium
,
Prostate Cancer
,
Solid Tumors
March 2015, Vol 6, No 2
Orlando, FL—A new retrospective study of 87,562 men diagnosed with prostate cancer between January 2005 and June 2013 show that the incidence of prostate cancer and men with prostate-specific antigen (PSA) >10 decreased gradually between 2005 and 2011. However, the incidence of high-risk prostate cancer at diagnosis increased annually by 3% between 2011 and 2013, totaling 6%. This increase could lead to an additional 1400 prostate cancer deaths 10 years later.
Read Article
AR-V7 Predicts Chemotherapy Sensitivity in Metastatic Prostate Cancer
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
March 2015, Vol 6, No 2
Orlando, FL—Experts are hopeful that the field of prostate cancer will soon be catching up to breast cancer and some other tumor types with regard to genomic markers. A study featured at the 2015 Genitourinary Cancers Symposium suggests that the androgen receptor (AR) abnormality known as “AR-V7” will turn out to be a predictive marker to help in treatment selection for patients with metastatic castration-resistant prostate cancer (CRPC).
Read Article
Multigene Test Stratifies Prostate Cancer Aggressiveness
By
Rosemary Frei, MSc
Prostate Cancer
October 2014, Vol 5 , No 8
Chicago, IL—The commercially available cell-cycle progression test known as Prolaris is helpful for stratifying risk for men with clinically localized prostate cancer and can help to modify treatment decisions for men with prostate cancer based on the aggressive nature of their tumor, according to a poster presented at the 2014 College of American Pathologists annual meeting by Michael K. Brawer, MD, Vice President of Medical Affairs, Urology, Myriad Genetic Laboratories, Inc, Salt Lake City, UT, and colleagues.
Read Article
New Practice Guideline for Systemic Therapy in Men with Metastatic Prostate Cancer
By
Rosemary Frei, MSc
Prostate Cancer
October 2014, Vol 5 , No 8
Anew guideline for systemic therapy in men with metastatic castration-resistant prostate cancer (mCRPC) is based on a literature review of recent publications and outlines the survival and quality-of-life benefits/toxicity effects of each recommendation (Basch E, et al.
J Clin Oncol
. 2014 Sept 8. Epub ahead of print).
Read Article
Upfront Docetaxel Markedly Improves Survival
By
Wayne Kuznar
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
August 2014, Vol 5, No 6
Chicago, IL—The upfront addition of docetaxel to androgen deprivation therapy (ADT) adds more than 1 year to overall survival (OS) compared with ADT alone in men with newly diagnosed hormone-sensitive prostate cancer, according to findings from a phase 3 study presented at the 2014 American Society of Clinical Oncology meeting.
Read Article
PSA Trend Analysis May Help Avoid Unnecessary Biopsies
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
June 2014, Vol 5, No 5
Orlando, FL—Delaying a prostate-specific antigen (PSA)-triggered prostate biopsy to allow for additional PSA assessments might have avoided more than 70% of subsequent biopsies, according to a study of negative biopsies for >28,000 men reported at the 2014 American Urological Association annual meeting.
Read Article
Enzalutamide Improves Survival After ADT in Patients with Metastatic CRPC
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
June 2014, Vol 5, No 5
Orlando, FL—Treatment with enzalutamide (Xtandi) after progression with androgen-deprivation therapy (ADT) led to a significant improvement in survival for men with metastatic castration-resistant prostate cancer (mCRPC), according to a new randomized trial reported at the 2014 American Urological Association annual meeting.
Read Article
Contrast-Enhanced Ultrasound a Promising, Inexpensive Diagnostic Tool for Prostate Cancer
By
Rosemary Frei, MSc
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
May 2014, Vol 5, No 4
Stockholm, Sweden—An inexpensive, noninvasive imaging modality is proving successful for verifying the presence of prostate cancer.
Read Article
Advances in the Treatment of Patients with Castration-Resistant Prostate Cancer
By
Wayne Kuznar
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
May 2014, Vol 5, No 4
Hollywood, FL—The treatment options for patients with castration-resistant prostate cancer (CRPC) have increased over the past few years. Understanding the clinical disease states is essential when choosing therapy for this patient population, according to Celestia S. Higano, MD, Professor of Medicine and Urology, University of Washington, Seattle, who described the recent additions to the therapeutic armamentarium at the 2014 National Comprehensive Cancer Network Conference.
Read Article
Imaging Choice May Influence Brachytherapy Outcomes
By
Charles Bankhead
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
April 2014, Vol 5, No 3
San Francisco, CA—Magnetic resonance imaging (MRI)-guided brachytherapy led to significantly less urinary dysfunction in men being treated for localized prostate cancer compared with ultrasound-guided techniques, according to a long-term prospective cohort study reported at the 2014 Genitourinary Cancers Symposium.
Read Article
Page 5 of 8
1
2
3
4
5
6
7
8
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma